Page 310 - Drug Class Review
P. 310
Page 185 of 205
Drug Effectiveness Review Project
To determine the effect of GAL on patients with probable VaD or AD combined with CVD
placebo N/A 6 months 196 Met clinical criteria for probable VaD based on NINDS-AIREN guidelines or AD based on NINCDS/ADRDA; significant radiological evidence of CVD; MMSE score of 10-25: ADAS-Cog score > 12; have a reliable caregiver; evidence of relevant focal neurological signs consistent with previous Evidence of neurodegenerative disorders other than AD; cognitive impairment resulting from cerebral trauma; hypoxic cerebral damage; vitamin deficiency; other clinically significant disease; patients who
Drugs Authors: Erkinjuntti et al. 90 Country: Multinational (10 countries) Janssen Research Foundation Setting: Multi-center (number of centers NR) galantamine 24 mg/d 6 months 396 received investigational medication within 30 days of trial Other antidementia medications not allowed; others NR
Alzheimer Year: 2002 Study design: RCT Sample size: 592 stroke or CVD
Final Report Update 1 Subgroups STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
